Duke University Medical Center, Durham, NC, USA.
Br J Pharmacol. 2012 Apr;165(7):2365-77. doi: 10.1111/j.1476-5381.2011.01725.x.
Inhalation of a β-adrenoceptor agonist (β-agonist) is first-line asthma therapy, used for both prophylaxis against, and acute relief of, bronchoconstriction. However, repeated clinical use of β-agonists leads to impaired bronchoprotection and, in some cases, adverse patient outcomes. Mechanisms underlying this β(2) -adrenoceptor dysfunction are not well understood, due largely to the lack of a comprehensive animal model and the uncertainty as to whether or not bronchorelaxation in mice is mediated by β(2) -adrenoceptors. Thus, we aimed to develop a mouse model that demonstrated functional β-agonist-induced β(2) -adrenoceptor desensitization in the context of allergic inflammatory airway disease.
We combined chronic allergen exposure with repeated β-agonist inhalation in allergen-treated BALB/C mice and examined the contribution of β(2) -adrenoceptors to albuterol-induced bronchoprotection using FVB/NJ mice with genetic deletion of β(2) -adrenoceptors (KO). Associated inflammatory changes - cytokines (ELISA), cells in bronchoalevolar lavage and airway remodelling (histology) and β(2) -adrenoceptor density (radioligand binding) - were also measured. KEY RESULTS β(2) -Adrenoceptors mediated albuterol-induced bronchoprotection in mice. Chronic treatment with albuterol induced loss of bronchoprotection, associated with exacerbation of the inflammatory components of the asthma phenotype.
This animal model reproduced salient features of human asthma and linked loss of bronchoprotection with airway pathobiology. Accordingly, the model offers an advanced tool for understanding the mechanisms of the effects of chronic β- agonist treatment on β-adrenoceptor function in asthma. Such information may guide the clinical use of β-agonists and provide insight into development of novel β-adrenoceptor ligands for the treatment of asthma.
β-肾上腺素受体激动剂(β-agonist)吸入是哮喘的一线治疗方法,既可预防,也可缓解支气管收缩。然而,β-激动剂的反复临床应用会导致支气管保护作用受损,在某些情况下,还会导致患者预后不良。由于缺乏全面的动物模型以及对小鼠支气管舒张是否由β-2 肾上腺素受体介导的不确定性,导致这种β(2)-肾上腺素能受体功能障碍的机制尚不清楚。因此,我们旨在建立一种在变应性炎症性气道疾病背景下表现出β-激动剂诱导的β(2)-肾上腺素能受体脱敏的小鼠模型。
我们将慢性变应原暴露与变应原处理的 BALB/C 小鼠重复吸入β-激动剂相结合,并使用β(2)-肾上腺素能受体基因缺失的 FVB/NJ 小鼠(KO),考察β(2)-肾上腺素能受体对沙丁胺醇诱导的支气管保护作用的贡献。还测量了相关的炎症变化 - 细胞因子(ELISA)、支气管肺泡灌洗液中的细胞和气道重塑(组织学)以及β(2)-肾上腺素能受体密度(放射性配体结合)。
β(2)-肾上腺素能受体介导了小鼠沙丁胺醇诱导的支气管保护作用。慢性沙丁胺醇治疗会导致支气管保护作用丧失,同时加剧哮喘表型的炎症成分。
该动物模型再现了人类哮喘的显著特征,并将支气管保护作用丧失与气道病理生理学联系起来。因此,该模型为理解慢性β-激动剂治疗对哮喘中β-肾上腺素能受体功能的影响机制提供了一个先进的工具。这些信息可能会指导β-激动剂的临床应用,并为开发新型β-肾上腺素能受体配体治疗哮喘提供思路。